Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. FTRE
FTRE logo

FTRE Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Fortrea Holdings Inc (FTRE) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Sell
Latest Price
10.440
1 Day change
0.58%
52 Week Range
18.670
Analysis Updated At
2026/04/17
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Fortrea Holdings Inc (FTRE) is not a good buy for a beginner, long-term investor with $50,000-$100,000 available for investment. The company's weak financial performance, declining revenue, negative ROIC, and insider/hedge fund selling trends indicate poor fundamentals. Additionally, the lack of positive trading signals and negative sentiment from analysts and news further support a sell recommendation.

Technical Analysis

The MACD histogram is positive and expanding, indicating a slight bullish momentum. However, RSI is neutral at 69.786, and moving averages are converging, showing no clear trend. The stock is trading near its resistance level (R1: 10.335), suggesting limited upside potential.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
7
Buy
7

Positive Catalysts

  • NULL identified. The stock has no recent positive trading signals or significant catalysts to drive growth.

Neutral/Negative Catalysts

  • Declining revenue (-5.24% YoY in Q4

  • and negative net income (-46.90% YoY).

  • Insider and hedge fund selling activity has significantly increased.

  • Analysts have lowered price targets, and sentiment remains weak.

  • Poor business quality with a negative five-year average ROIC of -10.8%.

Financial Performance

In Q4 2025, revenue dropped to $660.5M (-5.24% YoY), net income fell to -$32.5M (-46.90% YoY), EPS declined to -0.35 (-48.53% YoY), and gross margin decreased to 16.93% (-1.74% YoY). These metrics highlight a deteriorating financial position.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analyst sentiment is mixed to negative. Barclays recently lowered its price target to $11, citing risks in the sector. Evercore ISI lowered its target to $14 but maintained an Outperform rating. TD Cowen upgraded the stock to Buy with a $15 target, but overall sentiment remains cautious with multiple downward revisions.

Wall Street analysts forecast FTRE stock price to rise
8 Analyst Rating
Wall Street analysts forecast FTRE stock price to rise
3 Buy
4 Hold
1 Sell
Hold
Current: 10.380
sliders
Low
7
Averages
15.33
High
25
Current: 10.380
sliders
Low
7
Averages
15.33
High
25
Barclays
Equal Weight
maintain
$12 -> $11
AI Analysis
2026-04-14
Reason
Barclays
Price Target
$12 -> $11
AI Analysis
2026-04-14
maintain
Equal Weight
Reason
Barclays lowered the firm's price target on Fortrea to $11 from $12 and keeps an Equal Weight rating on the shares. The firm adjusted targets in the life science and diagnostic tools group as part of a Q1 preview. Barclays likes the setup for the sector but says it is "not without risk." Sentiment is at all-time lows and Barclays still believes in the "last-cut thesis (for the most part)," the analyst tells investors in a research note.
Evercore ISI
Outperform
to
NULL
downgrade
$25 -> $14
2026-04-08
Reason
Evercore ISI
Price Target
$25 -> $14
2026-04-08
downgrade
Outperform
to
NULL
Reason
Evercore ISI lowered the firm's price target on Fortrea to $14 from $25 and keeps an Outperform rating on the shares. The firm made several price target adjustments and additions to the firm's Tactical call lists as part of the firm's healthcare technology and distribution preview for Q1.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for FTRE
Unlock Now

People Also Watch